Evaluating outcomes in patients with anti-LGI1 encephalitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to prospectively evaluate clinical outcomes in patients diagnosed with anti-LGI1 encephalitis, a type of autoimmune encephalitis. The study will recruit newly diagnosed patients during the acute stage and will utilize a variety of advanced paraclinical examinations, including blood tests, MRI, EEG, and neuropsychological assessments. By analyzing these clinical features and outcomes, the researchers hope to identify factors associated with the disease's progression and treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis.
2. Newly diagnosed, and during the acute stage before study enrollment.
3. Sign the informed consent form.

Exclusion Criteria:

1. with the diagnosis of epilepsy, stroke, cerebral trauma, and/or other nervous system disease prior to the onset of encephalitis.
2. with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody.
3. Lost to follow-up.

Where it's running

• 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Chun-Hong Shen — 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
• Study coordinator: Mei-Ping Ding
• Email: dmp-neurology@zju.edu.cn
• Phone: +86 0571 87783872

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pregnant Women with Neuroimmune Diseases: A long-term follow-up study

  This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07653984

• Identifying new autoantibodies and causes of autoimmune encephalitis

  This project looks for new autoantibodies and other disease features in adults with autoimmune encephalitis to help improve diagnosis and care.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07477015

• ART5803 for people with anti-NMDAR encephalitis or anti-NMDAR autoantibody–linked psychiatric disease

  This will test whether ART5803, a one‑armed antibody, is safe and can help adults with anti‑NMDAR encephalitis or anti‑NMDAR autoantibody‑associated psychiatric symptoms.

  Recruiting Phase 2 Arialys Australia Pty Ltd · Seoul · NCT07093333

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Using Calculus Bovis Sativus to treat adult encephalitis

  This study is testing a traditional Chinese medicine called Calculus Bovis Sativus to see if it can help adults with autoimmune encephalitis feel better.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06584045

• Identifying biomarkers for autoimmune diseases affecting the nervous system

  This study is trying to find specific markers in the blood of people with autoimmune diseases affecting the nervous system, like Multiple Sclerosis, to help with early diagnosis and better treatment options.

  Recruiting Tongji Hospital · Wuhan · NCT06502015

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.